Reaction

Monoplegia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,311 reports · 89 co-occurring drugs

As of the last recalculation, Monoplegia appears in 4,311 FAERS reports alongside 89 co-occurring drug terms. The strongest observed disproportionality signal is BLEOMYCIN SULFATE (PRR 15.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Bleomycin Sulfate	32	15.1	15.1
Bupivacaine	22	11.4	11.4
Fondaparinux Sodium	14	8.4	8.4
Mesna Injection	14	8.2	8.2
Peginterferon Beta-1A	22	8.1	8.2
Mesna	14	8.1	8.1
Siponimod	13	7.1	7.1
Methylprednisolone Acetate	11	6.6	6.7
Rocuronium Bromide	13	5.3	5.3
Baclofen	93	5.3	5.3
Ofatumumab	36	5.3	5.3
Human Immunoglobulin G	21	4.9	4.9
Heparin Sodium	14	4.9	4.9
Fingolimod Hcl	85	4.8	4.8
Lidocaine Hydrochloride And Epinephrine Bitartrate	50	4.6	4.6
Interferon Beta-1A	171	4.4	4.4
Sodium Bicarbonate	21	4.4	4.4
Sodium Bicarbonate Injection,	21	4.4	4.4
Glatiramer Acetate	53	4.3	4.3
Fam-Trastuzumab Deruxtecan-Nxki	9	4.3	4.3
Interferon Beta-1B	17	4.3	4.3
Diazepam Oral Solution (Concentrate)	78	4.3	4.3
Diazepam Oral	78	4.3	4.3
Lidocaine Hydrochloride	52	4.2	4.2
Valsartan Oral	46	4.1	4.1
Clonidine	43	4.1	4.1
Letrozole Tablets	39	3.9	3.9
Valsartan And Hydrochlorothiazide	11	3.9	3.9
Dalfampridine	57	3.9	3.9
Lidicaine	39	3.9	3.9
Burn Relief	39	3.9	3.9
Lidocaine Hydrochloride And Epinephrine	39	3.9	3.9
Letrozole	47	3.7	3.7
Diazepam	92	3.7	3.7
Valsartan	79	3.7	3.7
Enoxaparin Sodium	43	3.6	3.6
Propofol	27	3.6	3.6
Darunavir	11	3.5	3.5
Sorafenib	15	3.5	3.5
Sevoflurane	6	3.5	3.5
Pregabalin	189	3.5	3.5
Fentanyl	69	3.4	3.4
Tizanidine	16	3.2	3.2
Diroximel Fumarate	8	3.2	3.2
Etoposide	49	3.2	3.2
Extended Phenytoin Sodium	11	3.2	3.2
Botulinum Toxin Type A	8	3.1	3.1
Insulin Glargine-Yfgn	14	3.1	3.1
Drospirenone And Ethinyl Estradiol	28	3.1	3.1
Natalizumab	111	3.0	3.0
Cytarabine	37	3.0	3.0
Bicalutamide	9	2.9	2.9
Lapatinib	9	2.8	2.8
Ifosfamide	12	2.7	2.7
Dimethyl Fumarate	68	2.7	2.7
Pazopanib Hydrochloride	15	2.7	2.7
Glimepiride	21	2.6	2.6
Ocrelizumab	33	2.6	2.6
Sunitinib Malate	20	2.5	2.5
Onabotulinumtoxina	38	2.4	2.4
Doxorubicin Hydrochloride	16	2.4	2.4
Asenapine Maleate	4	2.2	2.2
Carfilzomib	13	2.2	2.2
Enzalutamide	26	2.1	2.1
Teriflunomide	20	2.1	2.1
Gefitinib	4	2.1	2.1
Erlotinib	4	2.0	2.0
Doxorubicin	36	2.0	2.0
Cortisone Acetate	5	2.0	2.0
Erlotinib Hydrochloride	5	1.9	1.9
Pegfilgrastim	39	1.9	1.9
Suvorexant	5	1.9	1.9
Aflibercept	12	1.9	1.9
Rifaximin	8	1.8	1.8
Fremanezumab-Vfrm	4	1.7	1.7
Buprenorphine	32	1.7	1.7
Teriparatide	38	1.6	1.6
Dabigatran Etexilate Mesylate	23	1.5	1.5
Axitinib	6	1.5	1.5
Axicabtagene Ciloleucel	3	1.5	1.5
Benralizumab	6	1.4	1.4
Olaparib	6	1.4	1.4
Ipilimumab	12	1.3	1.3
Etonogestrel	13	1.3	1.3
Tafamidis	3	1.2	1.2
Paliperidone Palmitate	8	1.2	1.2
Abiraterone Acetate	10	1.2	1.2
Alirocumab	6	1.2	1.2
Nirmatrelvir And Ritonavir	8	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.